Focused On-demand Library for Small ribosomal subunit protein mS27

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q92552

UPID:

RT27_HUMAN

Alternative names:

28S ribosomal protein S27, mitochondrial; Mitochondrial ribosomal protein S27

Alternative UPACC:

Q92552; B4DRT2; Q6P1S1

Background:

Small ribosomal subunit protein mS27, also known as 28S ribosomal protein S27, mitochondrial, and Mitochondrial ribosomal protein S27, is a crucial RNA-binding component of the mitochondrial small ribosomal subunit (mt-SSU). It plays a pivotal role in mitochondrial protein synthesis, stimulating mitochondrial mRNA translation of subunit components of the mitochondrial electron transport chain. Furthermore, it binds to the mitochondrial 12S rRNA and tRNA(Glu), showcasing its multifaceted role in cellular function.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein mS27 could open doors to potential therapeutic strategies, especially considering its involvement in positive regulation of cell proliferation and tumor cell growth. This insight offers a promising avenue for the development of novel treatments targeting mitochondrial dysfunctions and cancer.